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                                  INTRODUCTION
The  most  common  and  distressing  symptoms,  which  follow  anaesthesia  and 
surgery are pain and emesis. Sometimes nausea and vomiting may be more distressing 
especially after minor and ambulatory surgery, delaying the hospital discharge. Yet it 
may be a major factor in upsetting the post-operative convalescence. 
It is common after spinal anaesthesia for caesarian section with reported incidence 
as high as 66%. Available large number of agents which prevent emesis indicate the 
magnitude of the problems and lack of satisfactory results. 
Nausea  and  vomiting  has  been  associated  for  many  years  in  use  of  general 
anaesthesia (i.e.) ether and chloroform. Extensive description of postoperative nausea 
and vomiting has been given by Sir John Snow in 1948 within 18 month of chloroform 
introduction. 
In pregnancy, there is always an increased frequency of nausea and vomiting due 
to various possibilities.  These factors  added to the spinal  anaesthesia,  and effects  of 
sympathetic block, and the anxiety may increase the frequency of nausea and vomiting 
in the post operative period starting from the intra operative period. 
Though there are many drugs available in treating the nausea and vomiting, we 
are  more  concerned in  prevention  of  the  problem with  the  help  of  pharmacological 
agents. 
The purpose of this double blind randomised study was to assess the efficacy of 
the  following  drugs  such  as  ondansetron,  glycopyrrolate,  metoclopramide  + 
dexamethasone combination in  prevention of nausea and vomiting in pregnant women 
undergoing  caesarean  section  under  spinal  anaesthesia,  by  using  the  drugs 
prophylactically.    
This study is undertaken with atmost care and the results are discussed. 
AIM OF THE STUDY
To compare the efficacy of ondansetron, metoclopramide plus dexamethasone and 
glycopyrrolate as a prophylactic antiemetic agent in prevention of postoperative nausea 
and vomiting after spinal anaesthesia for caesarean delivery. 
REVIEW OF LITERATURE
1] A comparative study of  glycopyrrolate,  dexamethasone and metaclopramide in 
control  of  post-operative  nausea  and vomiting  after  spinal  anaesthesia  for  caesarean 
delivery [Dr. Biswas et al – Indian J Anaesthesia) 2003 47.3]
The study was conducted in 80 women – allocated into 4 groups of 20 each. A-Inj 
glycopyrrolate 0.2 mg, B – Inj Dexamethasone 8mg, C-Inj – Metoclopramide 10mg, D – 
normal  saline  2ml  (control).  The  incidence  of  nausea  and vomiting  was  less  in  the 
glycopyrrolate group. P value <0.05.  The incidence was 40% in the placebo group, 10% 
in  the  glycopyrrolate  group,  10%  in  the  dexamethasone  group  and  20%  in  the 
metoclopramide group.
2] Double  blind  cross  over  study  of  comparison  of  antiemetic  efficacy  of 
dexamethasone 8mg versus high dose metaclopramide in caesarean section under spinal 
anaesthesia [Ms. Aapro et al – Journal of clinical gynecology vol. 2   2003].
Two group of 50 each were compared and there was reduction in post operative 
nausea vomiting in the metaclopramide group. (P <0.05)
3] Combination of granisetron and dexamethasone decreases post operative nausea 
vomiting  in  regional  anaesthesia  in  lower  limb  surgeries  [Fujii  et  al,  Dept.  of 
Anaesthesiology, Toridl Gen Hospital, Tokyo 2003).
Granisetron  20μ/kg  +  Dexamethasone  8mg  has  reduced  incidence  of  nausea 
vomiting by 27% compared to the control group.
4] Comparison of Ondansetron versus placebo for nausea and vomiting in caesarean 
section  under  subarachanoid  block  -  EI  Abouliesh  et  al  [Journal  of  Anaesthesia  – 
Association of Anaesthetists of Great Britain and Ireland, Vol. 54].
Seventy  four  patients  were  divided  into  2  groups.  The  drug  was  given 
(Ondansetron 4mg) before induction during preloading.
The incidence of nausea vomiting was reduced in the Ondansetron group. 
The  incidence  of  nausea,  vomiting  was  85%  in  placebo  group  and  34%  in 
ondansetron group (p<0.028). 
5] Prospective double blind study – comparison of ondansetron, ondansetron plus 
dexamethasone, dexamethasone as prophylaxis for post operative nausea vomiting for 
day care gynaecology surgeries – Thomas et al (Dept. of Anaesthesia, South Hampton 
Gen Hospital, UK 2002).
The study was conducted in 150 females 50 in each group. The dexamethasone 
plus ondansetron group was superior  in reduction of post  operative nausea vomiting 
among the three groups (p<0.05).
6] Double blind study – comparison of efficacy of metoclopramide and ondansetron 
– for prophylaxis for post operative nausea and vomiting for caesarean section under 
spinal anaesthesia – F.J. Horea – Mignel MD et al, Hospital General de Sogoria [2001]. 
This  was  a  double  blind  placebo  controlled  study  50  women  in  each  group. 
Nausea and vomiting was seen in 11.5% of total cases. 91.8% of ondansetron group had 
no  vomiting  and  91.6%  of  metoclopramide  had  no  vomiting.  Increased  emetic 
symptoms  were  noted  during  umbilical  cord  clamping.  There  was  no  statistically 
significant difference between ondansetron and metoclopramide group (p<0.01).
7] Double blind prospective study – evaluating efficacy of 200μ of glycopyrrolate iv 
before  induction  for  caesarean  patients  using  2.5ml  isobaric  bupivicaine  spinal 
anaesthesia – BJ of Anaesthesia 1995 Sep. Ure – D James KS et al. 
This  study was done in 50 women coming for  caesarean section under  spinal 
anaesthesia. Glycopyrrolate decreased frequency of vomiting and ephedrine requirement 
in pregnancy patients (p<0.02).
8] Prophylactic  single  dose  intravenous  administration  of  ondansetron  in  the 
prevention of postoperative – emetic symptoms during spinal anaesthesia for caesarean 
delivery – Dr. A.K. Pan, Dr.A. Rend. [2002]
In a placebo controlled study 40 women were studied, 4mg of ondansetron was 
administered  iv  before  spinal  anaesthesia.  The  frequency  of  nausea  was  75%  after 
placebo  and  10%  after  ondansetron.  The  corresponding  frequency  of  retching  and 
vomiting were 60% after placebo and 5% after ondansetron. 
HISTORICAL ASPECTS IN POSTOPERATIVE 
NAUSEA AND VOMITING
During ether era, reported incidence of post operative nausea and vomiting was as 
high as 75-80%. Various techniques including olive oil and glucose insulin injection 
were reported to be effective as reported by Robert Ferguson in 1912. The effect of 
atropine was appreciated by Brown Sequard as early as 1883. 
In second half of the century the incidence of post operative nausea and vomiting 
decreased to about 50% due to the use of non opoid, non-ether, regional anaesthetic 
techniques, refinement of surgical techniques and identification of patient’s predictive 
emetogenic factors.  There are 3 kinds of vomiting, the first of which is attributed to 
anaesthetics  such  as  ether,  second  due  to  the  reflex  responses,  third  due  to  the 
medication used intraoperatively. Subsequent investigation unfolded a spectrum of non-
anaesthetic factors in the pathogenesis of post operative nausea and vomiting. 
Over  years  numerous  of  drugs  have  been  used  in  the  management  of  post 
operative nausea and vomiting. Phenothiazines were synthesized in late 19th century by 
chemists  in  dyeing industry.  Promethazines  were  found in  1930 to  have  good anti-
emetic property. However sedative action of it, limited its use. Phenothiazine derivatives 
have been exclusively used in the treatment of post operative nausea and vomiting. 
The  recent  introduction  of  the  5HT3 antagonists  such  as  ondansetron  and 
granisetron have reached good heights in the treatment of nausea and vomiting. 
There  are  new  antiemetics  like  neurokinin-1,  (substance-P  antagonists)  in 
development. 
The reason for the magnitude of the problem of  PONV persisting inspite of the 
various drugs in use can be assessed by four factors. 
1. Complexity of the problem: The variables are many that it becomes difficult to 
assess the effects of an intervention as it requires considerable number of patients 
of well controlled trials. 
2. Inadequate  qualification  of  phenomena: The  phenomena  has  been  poorly 
qualified i.e. nausea, vomiting, retching etc. 
3. Inadequate  antiemetic  regimen:  Unable  to  identify  a  good  drug  which  can 
prevent nausea and vomiting. 
4. Animal Model: A lack of model to study the physiology and pharmacology of 
mechanism of  PONV, though monkey and dogs are available they don’t suffer 
from pregnancy induced vomiting and motion sickness and post  operative and 
post anesthetic emesis.   
 
THE ANATOMY OF VOMITING CONTROL
There two areas which control or take part in the modulation of vomiting process. 
i) The vomiting centre
ii) The chemoreceptor trigger zone. 
The vomiting centre 
   The vomiting centre is located in the reticular formation of the medulla oblongata. 
These  take  part  in  the  initiation  of  vomiting  when  they  are  stimulated  by  certain 
circulating chemical agents. 
The chemoreceptor trigger zone
This centre is in or near the area postrema a ‘V’ shaped tissue in the lateral wall of 
the 4th ventricle near the obex. It’s a circumventricular organ. This shows response to 
gastric radiation sickness, uremia, morphine and other emetic agents. 
PHYSIOLOGY OF VOMITING
DEFINITIONS 
1. Nausea 
Its  an  unpleasant  sensation  referred  to  a  desire  to  vomit,  not  associated  with 
expulsive muscular movement. 
2. Retching 
When no stomach contents are expelled even with expulsive muscular efforts. 
3. Vomiting
It is the forceful expulsion of even small amount of upper gastrointestinal contents 
through mouth.
There are three major components of vomiting reflex, emetic detectors, integrative 
mechanism and motor output. 
The main sensors of somatic stimuli are located in the gut and chemoreceptor 
trigger zone. 
The emetic stimuli are detected from gut by 2 types of vagal afferent fibres. 
a) Mechanoreceptor: Located  in  muscular  wall  of  the  gut  and are  activated  by 
contraction  and  distension  of  the  gut,  on  physical  damage  and  manipulation 
during surgery of proximal gut may induce vomiting in over eating. 
b) Chemoreceptors: They are situated in the mucosa of upper gut and are sensitive 
to noxious stimuli. 
The CTZ (Chemoreceptor Trigger Zone) lies in the area postrema, which is able 
to  detect  the  circulatory  toxins  in  the  CSF and activates  the  vomiting  centre  in  the 
medulla. Afferent impulses from other areas of vestibular labrynthine (morning sickness, 
input from limbic system and visual cortex) can stimulate it.
The vomiting reflex is divided into two phases. 
i) The pre-ejection phase 
This  is  characterised  by  a  sensation of  nausea  associated with cold,  sweating, 
pupil  dilatation,  salivation  and  tachycardia  mediated  by  sympathetic  and  para 
sympathetic nerves. 
ii) The ejection phase 
This consists of retching and vomiting with expulsion of gastric contents. 
Causes of vomiting 
• Pharyngeal Stimulation 
• Gastrointestinal distension 
• Abdominal surgery 
• Anaesthetic agents 
• Pain 
• Opiod medication 
• Hypoxia – hypotension 
• Hypertension 
• Vestibular disturbances 
• Psychological factors 
• Pregnancy / Hormones 
Factors influencing post operative emesis 
1. Patient factors 
2. Pre operative factors 
3. Intra operative factors
a. Anaesthesia factors
b. Anaesthesia techniques 
c. Surgical factors  
4. Post operative factors  
Vestibular  cardiac  afferents  can  also  stimulate  the  vomiting  centre  as  in 
myocardial infarction.  
The vomiting centre in medulla is also in close proximity to other visceral centres 
like respiratory and vasomotor centres. Four types of receptors are involved in vomiting. 
• Cholinergic receptors (M)
• Dopaminergic receptors (D2)
• Histamine receptors (H1)
• Serotonergic receptors (HT3)
Integrative mechanism 
Its  a  co-ordination  between  many  physiological  systems  and  autonomic  and 
somatic components of nervous system – which occurs in brain stem. 
The motor  component  of  vomiting  reflex  is  mediated  by  both  autonomic  and 
somatic senses, and is coordinated by the vomiting system in the brain stem. The vagal 
neurons that supply the gut and the heart originate in the dorsal motor vagal nucleus and 
nucleus ambigus. The dorsal and ventral respiratory group which regulate the phrenic 
nerve output from the cervical spine, are parasympathetic neurons. The output of these 
nuclei are coordinated to produce the physiologic pattern associated with vomiting. 
1. PATIENT FACTORS 
a. Age: The incidence of nausea and vomiting is 5% in infants, 25% below 5 yrs, 
42-51% in 6-16 group and 42-51% in adults. 
b. Gender: Adult women have 2-4 times greater incidence than men due to female 
hormones. 
c. Obesity:  Increased frequency of nausea and vomiting is seen because adipose 
tissue store anaesthetic agents excessively and may also produce excess estrogen. 
d. H/o motion sickness: Increased risk of PONV in this group. 
e. Delayed  gastric  emptying:  In  patients  with  intra  abdominal  pathology 
pregnancy,  diabetes  mellitus,  hypothyroidism,  increased  ICT,  H/o  swallowing 
blood, full stomach have increased risk of nausea and vomiting. 
f. Smokers: Non smokers are more prone to than smokers.     
2. PREOPERATIVE FACTORS 
a. Food: Prolonged pre-operative fasting or recent intake of food can both increase 
the incidence. 
b. Anxiety: Both psychological stress and anxiety predisposes to emesis. 
c. Reasons for surgery:  Surgery associated with increased ICT, GIT obstruction, 
pregnancy, abortion or cancer patients on chemotheraphy, have increased risk of 
emesis. 
d. Premedication:  Atropine  delays  gastric  emptying and lowers  the oesophageal 
tone, opiods like morphine and pethidine decreases gastric motility and gastric 
emptying. This enhances the release of 5HT from chromaffin cells and releases 
ADH, also stimulates CTZ.
3. INTRAOPERATIVE FACTORS  
1. Anaesthesia factors 
a. Intubation: Stimulation of pharyngeal mechanoreceptor afferents lead to emesis. 
b. Anaesthetics:  Deeper  plane  of  anaesthesia  or  gastric  inflation  during  mask 
ventilation may be a causative factor.
c. Anaesthesia:  Head  movement  of  patient  after  awakening  leads  to  sudden 
vestibular change and increase incidence of PONV.
d. Anaesthetic drugs: Opiods, etomidate, and methohexital are associated with high 
rates of PONV. 
e. Inhalational  agents:  Ether  and  cyclopropane  increase  the  risk  of  PONV 
Nitrousoxide  too  has  a  significant  role  in  causing  nausea.  The  proposed 
mechanism of N2O emesis is its action on opiod receptors, changes in middle ear 
pressure, sympathetic nerve stimulation and gastric distension. 
2. Anaesthetic techniques  
The incidence is said to be lower in spinal than in general anaesthesia. Regional 
anaesthesia is associated with lower incidence. 
3. Surgical factors 
            Ophthalmic surgery, ENT surgery, abdominal surgery, gynecological surgery are 
associated with increased incidence. 
4. Post operative factors 
Pain, dizziness, early ambulation, early intake of food increases the incidence. 
FACTORS WHICH INCREASE THE RISK OF PONV IN 
REGIONAL ANAESTHESIA PATIENTS
Patient factors 
1. Age: Younger age has an increased risk of postoperative nausea and vomiting 
compared to middle age groups. Age >60yrs also have increased incidence.   
2. Gender:  Increased  risk  of  nausea  and  vomiting  in  the  female  sex  than  in 
males. There is also relation of to the menstrual cycle.  
3. Other factors: 
• H/o motion sickness
• Non smokers > smokers 
• Obesity 
All the factors have increased risk of PONV. 
Systemic anaesthetic factors  
1. Premedication:  The  role  of  premedication  in  regional  anaesthesia  remains 
largely  uninvestigated.  No  conclusion  can  be  drawn  from  various 
premedications given except the opiods which remain at risk. 
2. Introperative sedation: Many patients may receive intraoperative sedation to 
supplement  the  regional  anaesthesia,  to  improve  patient  acceptability  and 
comfort, and to reduce the stress and anxiety, while clonidine, propofol and 
midazolam have no effect on PONV, other drugs like methohexital γ-hydroxy 
butyrate and etomidate have increased risk. 
3. Hydration: Another factor that has been implicated is dehydration. If there is 
dehydration,  there  is  increased  risk  of  PONV.   Probably  this  effect  of 
dehydration in equated to blood pressure.
4. Intrathecal  medications:  Increased  risk  of  PONV  in  patients  where 
intrathecal opiods, are used with local anaethetics.  
Post – operative factors 
There is increased risk of PONV when there is increased post operative pain. This 
post – operative pain if treated by opiods may therefore increase the risk of PONV. 
THE FACTORS WHICH LEAD TO INCREASED RISK OF 
PONV IN PREGNANCY PATIENTS DURING CAESAREAN 
SECTION
PATIENT FACTORS 
1. There  is  always  increased  anxiety  stress  and  pain  when  the  female  is 
coming for caesarean section which itself increases the risk of PONV. 
2. The  retardation  of  gastro-intestinal  motility  and  the  condition  of  the 
stomach fullness has an independent risk of nausea and vomiting. 
3. Increased compression of the stomach due to the gravid uterus may cause a 
problem. 
4. Decreased lower oesophageal tone due to the hormone progesterone has an 
increased risk of vomiting. 
5. The presence of female hormones oestrogen, progestrone, human chorionic 
gonadotropin in increased levels, add to the risk of nausea and vomiting. 
6. Anatomical  changes in  esophageal  gastic  junction increases  the risk  of 
vomiting.  
7. The addition of any opiods or other analgesics in the labour room or ward 
may intern increase the risk of nausea and vomiting.  
INTRAOPERATIVE FACTORS 
1. Intraoperative hypotension: Intra operative hypotension has a greater influence 
in  the  issue  of  nausea.  When  there  is  a  greater  deal  of  hypotension,  there  is 
increased risk of nausea and vomiting.
2. Intraoperative  O2 supplementation:  It  has  been  found  out  that  O2 
supplementation  during  the  caesarean  section  have  reduced  the  incidence  of 
PONV. 
3. Intraoperative sedation: Avoidance of intraoperative opiod sedations and use of 
benzodiazepenes  such  as  midazolam  to  allay  the  anxiety  have  reduced  the 
incidence of PONV. 
4. Intraoperative medications: Intra operative medications given systemically such 
as  prostoglandins,  methergine  have  increased  the  incidence  of  postoperative 
nausea and vomiting. 
5. Surgical factors: 
i. The compression of uterus from outside the abdominal cavity to deliver the 
baby, has an increased roll to play in the risk of nausea and vomiting. 
ii. The manual delivery of placenta by compression of uterus and pulling the 
umbilical cord, is one of the important periods, where the patient complains 
of nausea. 
iii. The  exteriorization  of  the  uterus  to  secure  the  bleeding  points  and 
compressing  of  the  uterus  to  prevent  post  partum hemorrhage,  pull  the 
peritoneal attachments and have increase release of vagal discharge, which 
is a critical period of nausea and vomiting.  
POST OPERATIVE FACTORS 
i) The anxiety plays an important role in the post operative period. 
ii) The quick decent of the local anaesthetic, and if the patient experiences pain, it 
may increase the risk of post-operative nausea and vomiting. 
iii) Early ambulation may have an important role to play in PONV. 
iv) Early oral feeds may also cause increased incidence of PONV.  
PHARMACOLOGIST VIEW OF EMETIC STIMULI
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Group and drugs Mechanism of actionD2 M H2 5HT
Side effects
PHENOTHIAZONES 
1. Fluphenazine 
2. Chloropramazine 
3. Prochlorperazine 
4. Promethazine 
++++
++++
+++
+
++
++
++++
-
+
• Sedation
• Extra 
pyramidal side 
effects 
• Cholestatic 
jaundice 
• Hemolytic 
abnormality 
• Skin 
sensitization 
• Hypotension 
ANTI-HISTAMINES
1. Diphenhydramine
2. Promethazine 
3. Cyclizine 
4. Meclizine 
5. Hydroxyzine 
+
++
++
++
++++
++++
-
-
• Sedation 
• Drowsiness 
• Depression 
• Dry mouth 
BUTYRO-
PHENONES
1. Haloperidol 
2. Droperidol 
3. Domperidone 
++++
++++
++++
-
-
-
+
+
+
-
• Drowsiness 
• Restlessness 
• Extrapyranidal 
side effects
ANTI-
CHOLINERGICS
Hyoscine/Scopalamine
Atropine
+ ++++ + -
Dryness of 
mouth, 
tachycardia, 
mydriasis 
retention of urine
PROKINETICS
1. Benzamides
     (Metaclopramide)
2. Thiobenzamides 
3. Benzimidazole 
derivative 
(Domperidone)
4. Benzamide 
5. derivatives cisaprid
6. Substituted 
benzamides. 
Batanopride/ 
Zacropride
+++ - + ++
Dysrrhythmias 
galactorrhoea. 
Gynecomastia 
Amenorrhorea 
Constipation 
Diarrhoea 
Extrapyramidal 
side effects 
5HT3 
ANTAGONISTS 
Ondansetron 
Granisetron 
Tropisetron 
Dolasetron 
- - - ++++
Allergic reactions 
Dysarrythmia 
Bronchospasm 
Blurred vision 
Non – pharmacologic approach 
• Acupuncture
• Acupressure 
 Manual  electric  stimulation  of  the  P6  Acupuncture  point  by  needle  results  in 
decrease in incidence of PONV upto 6 hrs. Application of pressure on P-6 patient every 
2  hrs  is  reported  to  produce  effect  for  24  hrs.  
The vomiting reflex 
The act of vomiting is a complex, almost convulsive reflex maneuver involving 
both visceral and striated muscle. Vomiting begins with deep inspiration, elevation of 
the soft palate to occlude the naso pharynx and glottic closure. Then the proximal area of 
the stomach relaxes and a giant contraction of the small intestine forces the previously 
ingested  contents  to  the stomach diluting and buffering the gastric  acid.  Finally  the 
contraction  of  the oesophagus  muscles  pull  the  stomach into the  thorax  forming an 
oesophageal  funnel  and  food  is  forced  out  of  the  stomach  by  contraction  of  the 
abdominal  muscles  against  the lowered diaphragm. If  glottis  is  closed only retching 
occurs, if the pharynx is relaxed the content is exited through the mouth. 
Several autonomic signs precede vomiting. The warning signs include excessive 
salivation, dilated pupils, tachypnoea, swallowing, pallor, sweating and tachycardia. If 
nausea proceeds to retching bradycardia may replace tachycardia. 
PEPTIDES IMPLICATED IN CAUSING NAUSEA AND VOMITING 
Nor – epinephrine 
ACTH
Vasopressin Bombesin 
Human chorionic gonadotropin Thyrotropin releasing hormone
Angiotensin – II Peptide 77
Leu-Enkephalin Neurotensin 
Met. Enkephalin Vasoactive intestinal peptide
Cholecystokinin
Insulin 
Gastrin 
Oxytocin 
PHYSIOLOGICAL COMPLICATIONS OF VOMITING
 
There are several physiological complications of nausea and vomiting that are of 
concern to the anaesthetist. Possible complications include the following:
1. Aspiration pneumonitis 
In an unanaesthetized patient laryngeal reflexes accompany the vomiting reflex, 
preventing  aspiration  of  the  gastric  contents.  If  the  laryngeal  reflexes  are  blunted 
however vomiting can result in regurgitated gastric contents entering the trachea with 
attendant risk of aspiration pneumonitis. 
2. Visceral and wound dehiscence 
  The act of vomiting causes a considerable increase in both intrathoracic and intra 
abdominal  pressure.  If  the pharyngeal  sphincter is  incompletely relaxed at  this time, 
oesophageal rupture can occur. Severe retching and vomiting can lead to a syndrome 
called Mallory – Weiss lear. In post surgical setting the rise in intraabdominal pressure 
can stern visceral anastomosis as well  as dehiscence of wound closures.  It  may also 
initiate post surgical bleeding secondary to raised intravascular pressure. 
3. Electrolyte disorders 
Severe prolonged vomiting such as  that  seen in children with pyloric  stenosis 
causes  electrolyte  depletion,  dehydration  and  gastric  acid  loss.  The  predominant 
resultant disorder is metabolic alkalosis. Hypokalemia and hyponatremia can occur as 
well and are exacerbated by renal exerction of K+ and Na+ in an effort to conserve H+.
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PHARMACOLOGY
Metoclopramide 
Metoclopramide comes under the group of substituted benzamides. They are the 
derivatives of para-amino benzoic acid and are structurally related to procainamide. 
The chemical structure of metaclopramide is shown below
Metoclopramide
 
Metoclopramide  is  one  of  the  oldest  true  prokinetic  agents.  Its  administration 
results in coordinated contractions that enhance transit. Its effects are confined largely to 
upper digestive tract where it increases lower oesophageal sphincter tone and stimulates 
antral and small intestinal contractions. Despite having invitro effects on the contractility 
of colonic smooth muscle, the drug has no significant effect on the motility of the large 
bowel.  
Mechanism of action 
The mechanism of action of metoclopramide is complex. In general agents of this 
class facilitate Ach release from the enteric neurons, an action that may be mediated 
indirectly by several different mechanisms, which include suppression of 5HT3 receptors 
and stimulation of excitatory neurons via 5HT4 receptors. In addition metoclopramide is 
distinguished  from  agents  such  as  cisapride  by  having  both  central  and  peripheral 
antidopaminergic effects. The former is responsible for its anti-nausea and anti emetic 
effects,  whereas the latter  contributes  to  the prokinetic  activity  by  concentrating the 
inhibitory effects of dopamine mediated via D2 dopaminergic receptors on cholinergic 
enteric neurons. 
Pharmacokinetics 
     Metoclopramide is absorbed rapidly after oral ingestion. Undergoes sulfation and 
glucronide conjugation in the liver and is excreted principally in the urine with a half life 
of 4 to 6 hrs. Peak concentration occur with about half an hour thereafter single oral 
dose with a duration of action that last to 1-2 hrs. 
Therapeutic use 
Metoclopramide has been used in patients with gastroesophagial reflux disease 
(GERD). It can produce symptomatic relief without necessarily promoting healing of the 
associated oesophagitis. Its clearly less effective than the modern day and suppressive 
medications like the proton pump inhibitors or even H2-receptor antagonists. And now 
metoclopramide is rarely used for treatment in GERD. 
Metoclopramide is indicated more often in patients with gastroparesis, in whom it 
may cause moderate improvement in gastric empting. 
Metoclopramide injections can be used as an adjunctive measure in medical or 
diagnostic  measures  such  as  intestinal  inhibition  or  contrast  radiography  of 
gastrointestinal tract. 
Although it has been used in postoperative ileus. Its effect on improving transit 
time in disorders of small bowel motility is limited. 
In general its greatest utility lies in its ability to ameliorate nausea and vomiting 
that often accompanies gastrointestinal dysmotility syndromes. The effect is mediated 
by dopamine receptor antagonism within chemoreceptor trigger zone. 
Metoclopramide has also been used in persistent hiccups. But its efficacy in this 
condition is equivocal at best. 
Metoclopramide is available at oral dosage forms and has parental preparation for 
intramuscular  and intravenous  use.  The  oral  dose  ranges  from 10-20mg three  times 
daily, 30 minute before meals. The onset of action within 30 to 60 minutes after an oral 
dose. In patients with severe nausea and vomiting 10 mg can be given intramuscularly 
(onset  of  action  10-15  minutes)  or  intravenously  (onset  of  action  1-3  minutes). 
Intravenous  dosing  for  patients  undergoing  chemotherapy  can  be  given  as  infusion 
1.2mg/kg of body weight administered over at least 15 minutes, beginning 30 minutes 
before chemotherapy and repeated if needed after 2-3 hours. The usual pediatric dose for 
gastroparesis is 0.1 to 0.2 mg per kg of body weight per dose given 30 minutes before 
meals and at bed time. 
Drug interactions 
   It hastens the absorption of many drugs example: aspirin, diazepam by facilitating 
gastric emptying. It reduces the extent of absorption of digoxin by allowing less time for 
it.  Bioavailability  of  cimetidine  is  also  reduced.  By blocking DA receptors  in  basal 
ganglia, it abolishes the therapeutic effect of levodopa. 
Adverse effects 
 The  major  side  effects  of  metoclopramide,  although  rare  can  be  serious  and 
include  extrapyramidal  effects  such  as  those  seen  with  phenothiazines.  Dystonias 
usually  occurring  acutely  after  intravenous  administration  and  parkinsonism  like 
symptoms which may occur several weeks after initiation of therapy. These generally 
respond to treatment (with an anti-cholinergic or anti-histamine) and are reversible after 
discontinuation of the drug. 
Tardive dyskinesia can also occur with chronic treatment (months to years) but 
may be irreversible.  Extrapyramidal  side effects  appear to occur  more commonly  in 
children  and  young  adults,  particularly  at  high  doses.  Like  domperidone  and  other 
dopamine  antagonists,  metoclopramide  can  also  cause  galactorrhea,  but  this  is 
infrequent. 
Methemoglobinemia has been reported occasionally in premature and full term neonates 
receiving metoclopramide. 
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ONDANSETRON
CHEMICAL STRUCTURE
CHEMISTRY, PHARMACOLOGICAL EFFECTS AND ACTION 
Ondansetron is the prototypical drug of the group of the class of 5HT3 antagonists. 
It  was introduced in the year  1990.  It  was a  widely used drug in the chemotherapy 
induced  emesis.  The  difference  to  the  other  drugs  in  its  class  such  as  granisetron, 
dolasetron, tropisetron is mainly by its chemical structure. 
Whether the main site of action of this drug is peripheral or central is not clear. 
There is  evidence that  effects  at  both the location contribute  to their  efficacy.  5HT3 
receptors are present  in several sites related to emesis,  including vagal afferents,  the 
NTS-Nucleus of tractus solitarius (which receive signals from vagal afferents) and the 
area postrema itself.  Serotonin is  released by the enterochromafin cells  of  the small 
intestine in response to the chemotherapeutic agents and may stimulate vagal afferents 
(via  5HT3 receptors)  and  initiate  the  vomiting  reflex.  Experimentally  vagotomy  has 
shown to prevent cisplatin induced emesis. However the highest concentration of 5HT3 
receptors in the CNS are found in NTS and CTZ. Antagonists of 5HT3 receptors may 
also suppress vomiting by acting on these sites. 
Pharmacokinetics 
The difference in plasma half lives of different 5HT3 receptor antagonists are not 
very  meaningful  in  practice  as  antiemetic  effects  persists  long  after  these  drugs 
disappear from the circulation. This suggests their continuing interaction at the receptor 
level. In fact all of these drugs can be administered effectively once a day. 
Ondansetron  is  well  absorbed  from the  gastrointestinal  tract.  It  is  extensively 
metabolized in the liver by cytochrome P450 pathway, followed by glucuronide and 
sulfate conjugation. Patients with liver dysfunction have a reduction in plasma clearance 
and some adjustment in dosage is advisable. Some reduction in ondansetron clearance is 
seen in elderly patients but no dosage adjustment is advised.
Therapeutic use 
Ondansetron is effective in treating chemotherapy induced nausea and in treating 
nausea  secondary  to  upper  abdominal  irradiation,  were  all  the  5HT3 antagonists  are 
efficacious. 
Ondasetron is also effective in hyperemesis of pregnancy and to post operative 
nausea, but not to motion sickness. 
Ondansetron is available as tablets, oral solution and intravenous preparation for 
injections.  For  patients  on  cancer  chemotherapy,  this  drug can  be  given in  a  single 
intravenous dose or  as a  continuous infusion over 15 minutes beginning 30 minutes 
before chemotherapy or  in 2 to 3 divided doses,  with the 1st dose given 30 minutes 
before and subsequent doses at various intervals in drug chemotherapy. 
For  post  operative nausea and vomiting,  this  drug can be given intravenously 
during the intra operative period. Reports of efficacy in vomiting associated with drug 
over  dosage,  side  effect  of  cotrimoxazole  and  fluvoxamine,  uremia  and  certain 
neurological injuries are also available.  
Adverse effects 
In  fact,  ondansetron  is  well  tolerated  with  the  most  adverse  effects  being 
constipation or diarrhea, headache and light headedness. A class of these agents have 
shown to induce minor electrocardiographic changes. But these are not felt clinically 
significant in most number of cases. Rashes and allergic reactions can occur specially 
after it injections. 
DEXAMETHASONE
Dexamethasone is a very potent and highly selective glucocorticoid. It is a long 
acting drug. 
PHARMACOLOGICAL ACTIONS 
1. Carbohydrate and protein metabolism 
Glucocorticoids promote glycogen deposition in the liver (They are analysed in 
the  basis  of  this  action)  by  inducing  hepatic  glycogen  synthetase  and  promoting 
glyconeogenesis.  It  inhibits  glucose  utilisation in  peripheral  tissues.  This  along with 
increased glucose release causes insulin resistance and a diabetes like state. It causes 
protein breakdown and amino acid mobilization from peripheral tissues, responsible for 
side effects like  muscle wasting. The amino acids are funneled into the liver and used 
for glyconeogensis. Excess urea is produced and these cause negative nitrogen balance.
Fat metabolism 
This action is primary permissive in nature. It promotes lipolysis due to glucagon, 
growth hormone, adrenaline and thyroxine. Cyclic adenosine mono phosphate (CAMP) 
induced breakdown of triglycerides are enhanced.  Fat  areas in various sites  respond 
differently  and redistribution  of  fat  occurs.  More  fat  is  deposited  in  the  face,  neck, 
shoulder – (moon face, fish mouth and buffalo hump), and there is loss of subcutaneous 
fat over the extremities. The explanation to this is because the peripheral adipocytes are 
less sensitive to insulin, and corticosteroid enhanced lipolytic action of adrenaline and 
growth hormone predominates. 
Calcium metabolism 
 It  inhibits  the  intestinal  absorption  of  calcium and increase  renal  excretion  of 
calcium. There is also loss of Ca from bone indirectly due to loss of osteoid in chronic 
use. Spongy bones (vertebra, ribs etc) are more sensitive. 
Water excretion 
Effect on water excretion is independent of action on Na transport, in maintaining 
GFR. 
In  adrenal  insufficiency  the  capacity  to  excrete  a  water  load  is  considerably 
reduced. 
Glucocorticoid enhances the secretory capacity of renal tubules. 
Cardiovascular system  
Glucocorticoids restrict capillary permeability and maintain tone of arteries and 
myocardial contractility.  It  has permissive effect  on pressor action of adrenaline and 
angiotensin.  They  also  play  a  role  in  development  of  hypertension  and  should  be 
cautiously used in hypertensives. 
Skeletal muscles 
Optimal  level  of  corticosteroids  are  needed  for  normal  muscular  activity, 
weakness may occur in both hypo and hypercortism but the effects may be different. 
Hypocortism – weakness due to hypodynamic circulation 
Hypercortism – excess glucocorticoid action → muscle wasting →  myopathy 
→ weakness. 
Central nervous system 
Mild euphoria is common with pharmacological doses of glucocorticoids. This is 
due to a direct effect on brain, independent of relief of disease symptoms, sometimes 
progresses to cause increased motor activity, insomnia, anxiety or depression. It also 
maintains the level of sensory perception and normal level of excitability of neurons. 
High doses, lower seizure threshold in epileptics. 
Stomach 
     Secretion of gastric acid and pepsin is increased and may aggravate peptic ulcer. 
Lymphoid tissue and blood cells 
Glucocorticoid drive can raise the rate of destruction of lymphoid cells      (T cells 
are  more  sensitive  than  B  cells).  However  a  marked  lytic  response  is  shown  by 
malignant lymphatic cells – usually in lymphomas. 
Corticosteroid  increases  the  number  of  RBCs,  platelets  and neutrophils  in  the 
circulation.  They decrease lymphocytes,  basophils and eosinophils.  These are  due to 
sequestration of cells. The count becomes normal in 24 hrs. 
Inflammatory responses 
Irrespective of type of injury or insult,  the attending inflammatory response is 
suppressed by glucocorticords. This is the basis of most of their clinical uses. It lowers 
all stages of inflammation. The action are direct and even local application is possible. 
The  cardinal  signs  of  inflammation  such  as  redness,  heat,  swelling  and  pain  are 
suppressed. 
Corticosteroids  are  only  palliative,  the  underlying  disease  processes  continues 
while manifestations are dampened. 
Immunological and allergic response  
They cause greater suppression of cell mediated immunity in which T cells are 
primarily involved example: delayed hypersensitivity and graft  rejection. It decreases 
the release of interleukin-1 and interleukin -2.
Pharmacokinetics 
 Dexamethasone is a water soluble ester, in the form of dexamethasone sodium 
phosphate. It has an oral, intramuscular or intravenous preparation. It acts rapidly and 
attain high concentration in tissue fluids. 
Dexamethasone  is  mainly  metabolized  in  the  liver  by  hepatic  microsomal 
enzymes. 
The t ½ of dexamethasone in greater than 36 hrs, its action starts within 30 minute 
of injection and action persists even after the drug disappears from the circulation. 
Drug interaction 
  Phenobarbitone and phenytoin induce metabolism of dexamethasone to decrease 
its therapeutic effect. 
USES 
1. Arthritis: Used in rheumatoid arthritis in conjunction with NSAIDs, arthritis in 
rheumatic fever and in gouty arthritis. 
2. Collagen  diseases: In  disease  like  systemic  lupus  erythematosus,  polyarteritis 
nodosa, dermatomyositis, this drug may be life saving.  
3. Severe allergic reactions: Used in anaphylaxis for short periods, in angioneurotic 
edema, urticaria, serum sickness.
4. Autoimmune  diseases: Autoimmune  hemolytic  anemia,  thrombocytopenia, 
active chronic hepatitis respond to corticosteroids. 
5. Bronchial asthma: Used intravenously in status asthmaticus. 
6. As an adjunct to drug in nausea and vomiting: As it prevent the release of 
inflammatory mediators and prostoglandins, they modulate neuronal activity and 
have  a  membrane  stabilising  action.  It  has  a  minimal  action  in  nausea  and 
vomiting. It increases the efficacy of the drug which is co-administered. 
7. Eye disease: Allergic conjuctivitis, iridocyclitis, keratitis
8. Intestinal disease: In diseases like crohns, ulcerative colitis, celiac disease with 
remissions and exacerbations.       
9. Cerebral  edema:  In  cerebral  edema  due  to  meningitis  and  tumours. 
dexamethasone is preferred because, it does not have Na retaining capacity. Large 
doses given in spinal injury can reduce neurological sequalae. 
10. Malignancies: As a component of chemotherapy, in ALL, Hodgkin’s and other 
lymphomas. 
11. In organ transplantations and skin allograft: To prevent rejection. 
12. To test adrenal – Pituatary axis function.  
Contraindications for chronic use 
These are only relative contraindications since, the steroid dexamethasone is a life 
saving  drug  they  are,  peptic  ulcer,  diabetes  mellitus,  hypertension,  viral  and  fungal 
infections,  tuberculosis  and  other  infections,  osteoporosis,  herpes  simplex  keratitis, 
psychosis, epilepsy, congestive heart failure, renal failure. 
 
GLYCOPYRROLATE
Glycopyrrolate is  a semisynthetic preparation of belladona and is a quartenary 
ammonium derivative. It is potent than any other anticholinergic compound but lacks 
CNS activity. 
Mechanism of action 
All the anticholinergic  drugs including glycopyrrolate  combine reversibly with 
cholinergic muscuranic receptor and prevent the access of acetylcholine to these sites. 
Molecular cloning of muscuranic receptors and its site 
M1 – CNS, stomach
M2 – Heart, CNS
M3 – CNS, salivary glands, airway smooth muscles
M4 – CNS, Heart
M5 – CNS 
 Muscuranic receptors are example of protein coupled receptors. 
Muscuranic cholinergic receptors that control salivary and bronchial secretions are 
inhibited by lower doses of glycopyrrolate, which can also cause effects on heart. 
Comparative effect of glycopyrrolate with other anticholinergic drugs
Glycopyrrolate Atropine Scopolamine 
Sedation 0 + +++
Antisialogogue ++ + +++
Increased heart rate ++ +++ +
Smooth muscle relaxation ++ ++ +
Mydriasis 0 + +
Decreased gastric secretion + + ?
Alteration  of  fetal  heart 
rate
0 0
• The variable antisialogogue dose of glycopyrrolate is 5 to 8μg/kg body weight. 
• Glycopyrrolate may increase metabolic oxygen consumption. 
• Glycopyrrolate  has  increased  potency  in  inhibiting  the  salivary  and  tracheal 
secretions compared to atropine. 
• It does not cross the blood - brain barrier so it has no action on the central nervous 
system. 
But it has increased vagal inhibitory action of vagal afferents from the intestine 
and blocks the vagal stimulation during anaesthesia and surgery, hence used to minimize 
the effect of handling during surgery.
MATERIALS AND METHODS
This is a prospective, double blind study conducted at Government Rajaji Hospital 
attached to Madurai Medical College. 
After approval by the ethical committee, 160 women of ASA grade I & II who 
came for caesarean delivery under spinal anaesthesia, were entered in this study. 
Women with history of hepatic dysfunction, history of previous post operative 
nausea and vomiting, diabetes patients, hypertensive patients, history of allergies to local 
anaesthetics,  and patients  with inadequate  starvation <6 hrs  were excluded from the 
study.  Patients  were  randomised  to  receive  one  of  the  combination  of  drugs 
intravenously  during  induction.  Only  injection  ranitidine  50mg  IV  was  given  as 
premedication. 
On arrival to the operation theatre, intravenous access was established and oxygen 
saturation by pulseoximeter was estimated continuously. Non invasive blood pressure 
monitor was attached to monitor the BP manually. Pulse rate and oxygen saturation was 
monitored by the pulseoximeter.  
The patients were preloaded with 500ml of crystalloids. 
Group MD (Metoclopramide plus dexamethasone)
These  patients  will  receive  injection  metoclopramide  10  mg  plus  injection 
dexamethasone 8 mg intravenously during preloading. 
Group OD (Ondansetron)
These  patients  will  receive  injection  ondansetron  4  mg  intravenously  during 
preloading. 
Group G (Glycopyrrolate)
These patients will receive injection glycopyrrolate 0.2 mg intravenously during 
preloading. 
Group C (the control group)
This is the group which will receive 2ml of normal saline IV during preloading.
Then the patients would by made to lie down in the right lateral position. After 
strict aseptic precautions subarachanoid block will be performed in L3 L4 space using 23 
gauge quinke spinal needle. The drug used was 1.8ml of 0.5% hyperbaric bupivicaine. 
After spinal anaesthesia, patients were put in supine position and draped. Then the 
surgery was proceeded. Pulse and the blood pressure were monitored continuously. If 
hypotension arised and if systolic BP reduces more than 20 percent from the baseline, 
injection ephedrine 6 mg intravenous was given. 
Injection methergine 0.2mg IV and injection oxytocin 10 mg in drip was routinely 
given after umbilical cord clamping of the baby. 
The patients were continuously monitored intraoperatively and post operatively 
for  any  nausea,  retching  or  vomiting.  The  follow  up  was  done  upto  4  hours 
postoperatively. 
Rescue antiemetic in the postoperative and intraoperative period will be injection 
ondansetron .4 mg IV, 
The patients sedation was also noted and graded. 
The nausea and vomiting response was graded as follows:
Emesis score
0 - No nausea 
1 - Mild nausea 
2 - Severe nausea 
3 - Retching 
4 - One episode of vomiting 
5 - Vomiting greater than 1 episode 
Parameters  which  were  also  observed  were  duration  of  surgery,  pulse  rate, 
systolic BP, sedation of the patient and APGAR of the baby. 
The sedation was graded as follows by Ramsay sedation score 
1 – Anxious 
2 - Co-operative and oriented 
3 – Responds to commands 
4 – Patient asleep – responds only to loud sound 
5 – Sluggish response 
6 – No response 
The study ends after 4 hours of surgery. 
STATISTICAL METHOD 
Results were established on mean ± standard deviation statistical significance was 
determined by students t test.
                                         OBSERVATION
In our study totally 160 patients were studied – Four groups of 40 each.  One 
group was the control group (group-C), and the other three group were designated as 
Group – G (glycopyrrolate group), Group – MD (Metoclopramide and Dexamethasone 
group), Group – OD (Ondansetron group). As in table I and II in the control group of 40, 
8 cases had intraoperative nausea and vomiting, 11 cases had intraoperative fall in BP, 
and  26  cases  had  postoperative  nausea  and  vomiting.  Rescue  antiemetic  injection 
ondansetron was given to 7 cases intraoperatively and 26 cases postoperatively totally. 
The occurrence of PONV was about 65% in the control group. In those 26 cases which 
had nausea and vomiting postoperatively, 6 cases had mild nausea, 8 cases had severe 
nausea, 8 cases retching and the remaining cases vomited once.
In the G-group (glycopyrrolate) out of the 40 cases, 12 cases had intraoperative 
fall  in  BP,  6  cases  had  intra-operative  nausea  and  vomiting  and  16  cases  had 
postoperative nausea and vomiting. Rescue anti-emetic injections ondansetron was given 
to 7 cases intraoperatively, who did not have PONV later. The occurrence of PONV was 
40%, ie., 16 cases out of 40. Out of them 6 cases had mild nausea, 3 cases had severe 
nausea, 4 cases had retching and the remaining cases vomited once. 
In the group-MD (Metoclopramide plus dexamethasone group) the fall in blood 
pressure was present in 13 cases. 4 cases had intraoperative nausea and vomiting. Post-
operative nausea and vomiting was seen in 7 cases out of the 40 cases. In those seven 
cases 6 cases had mild nausea and 1 case had retching. The occurrence of PONV in this 
group was 17.50 percent. 
In the O-group (Ondansetron group), 14 cases had intraoperative fall  in BP, 4 
cases had intraoperative nausea, 8 cases had postoperative nausea and vomiting. Out of 
the 8 cases of PONV, 5 cases had mild nausea, 1 case had severe nausea and 2 cases had 
retching. The occurrence of PONV was 20 percent.  
The observation are represented in the tables I, II and III.
DISCUSSION
In our study the occurrence of post operative nausea and vomiting was 65% in the 
control group. In the study conducted by A.K. Pan et al the occurrence of PONV was in 
75% in the placebo group of caesarean delivery under spinal anaesthesia and in the study 
conducted by Biswas et al the occurrence of PONV in placebo group was 40%
In the glycopyrrolate group the occurrence of post operative nausea was 40% in 
our study. Out of them 22% had nausea, 10% had retching and 7% had vomiting. In the 
study conducted by Biswas et al the occurrence of nausea was 10%.
In the ondansetron group the occurrence of nausea and vomiting was 20% in our 
study. Out of the 15% had nausea and 5% had retching. In the study conducted by Dr. 
A.K. Pan et al 2003. the ondansetron group had an incidence of 10% PONV. Versus 
75% in the placebo group. In his study there were cases of vomiting reported. But in our 
study no case had vomiting, only nausea and retching were reported.
In the metoclopramide plus dexamethasone group the incidence of PONV was 
17.5%. Out of those, 15% had nausea and 2.5% had retching. There was no report of 
vomiting.  In  the  study  conducted  by  Biswas  et  al  using  metoclopramide  alone  the 
incidence of PONV was 30%, whereas in our study by combining metoclopramide with 
dexamethasone,the incidence of PONV has been reduced to 17.5%.
Though in all the cases a little correlation between the fall in blood pressure and 
intraoperative and postoperative nausea vomiting, all the cases who had hypotension did 
not get nausea of vomiting. The correlation was not statistically significant. (P>0.05).
The intraoperative rescue drug was also taken into account in our calculation. The 
Null hypothesis was framed as there will be no nausea and vomiting postoperatively in 
the cases where the drugs were administered pre-operatively.
The P value was 0.9760 (P>0.05) Hence null hypothesis accepted.
Comparing the individual group, first  comparing the glycopyrrolate group with 
the ondansetron group, (OD group versus G group) and applying the student ‘t’ test , the 
P value obtained was 0.015,(P value <0.05). So there was significant difference between 
the drug  ondansetron and glycopyrrolate for  prevention of PONV. Moreover in the 
ondansetron  group there  were  only  8  cases  of  PONV compared  to  18  cases  in  the 
glycopyrrolate group.
While  comparing  the  metoclopramide  plus  dexamethasone  group  with  the 
glycopyrrolate group, the group MD had only 7 cases of PONV compared to 18 cases in 
the glycopyrrolate group (G). The test of significant value was 0.0068 (P<0.05). Hence 
the two groups were statistically significant. 
When  comparing  the  two  groups  metoclopramide  plus  dexamethasone  group 
(MD) and ondansetron (group – OD), 7 cases out of 40 cases had nausea and vomiting 
in the MD group and 8 cases out of 40 cases in the ondansetron group (OD).
The  test  of  significance  value  between  these  two  groups  was  0.77  (P-Value) 
(P>0.05).  Hence  there  two groups  showed no statistical  difference  between them in 
control  of  postoperative  nausea  and vomiting.  Though  in  the  patients  who received 
metaclopramide and dexamethasone, out of 7 cases only 1 case had retching and 6 cases 
had only mild nausea post operatively.
In the patients who received ondansetron out of 8 cases who had PONV, 5 cases 
had mild  nausea,  1  case  had severe  nausea  and 2  cases  had retching,  showing that 
metoclopramide  dexamethasone  combination  is  slightly  more  advantageous  than 
ondansetron group.
In  the  aspect  of  sedation,  the  metaclopramide  plus  dexamethasone  group  had 
average sedation score of 2.87,  most  of the people had the sedation score of 2 (co-
operative and oriented), 8 people had the sedation score of 4 (patient asleep, responds to 
loud sound).
In the ondansetron group all the patients had a sedation score of 2, (Cooperative 
and oriented).
In the glycopyrrolate group the patients had an average sedation score of 1.8% 
where as most of the patients had a score of 2(Cooperative and oriented).
SUMMARY AND CONCLUSION
 
The occurrence of postoperative nausea and vomiting in caesarean 
delivery under spinal anaesthesia can occur upto 67% without usage of 
prophylactic antiemetic drugs.
In fact in my study the occurrence of PONV was about 65%. The 
occurrence  of  peripartum emetic  episodes  are  infact  distressing  to  the 
patient and disturbing to the surgeons. Our main aim of the study was to 
find  out  a  good  prophylactic  anti-emetic  agent  to  prevent  the 
postoperative  emesis  of  caesarean  delivery  patients  under  spinal 
anaesthesia.
One hundred and sixty patients were allocated into four group of 
forty  each  and  they  received  glycopyrrolate  0.2m.gIV,  injection 
ondansetron 4 mg, injection metoclopramide plus dexamethasone 5 mg, 
and 2 ml   normal  saline randomly.  The drug was  given before  spinal 
anaesthesia during preloading.
The  occurrence  of  PONV in  the  control  group was  nearly  65% 
without any antiemetics.
56
In the comparing the other three groups, the incidence was 45% in 
glycopyrrolate. Though glycopyrrolate had reduced incidence of PONV it 
has not completely reduced it in a significant level. 
In the metoclopramide plus dexamethasone group, the occurrence 
of PONV was 17.5% and in the ondansetron group the occurrence was 
20%. Both the drugs significantly reduced the incidence of postoperative 
nausea and vomiting in the caesarean patients.  There was no statistical 
difference between these groups. But comparing the severity of nausea in 
the  patients  of  these  two  groups  ,  the  metoclopramide  group  patients 
showed less severity compared to the ondansetron group in number and 
emesis score.  
 Comparing  their  cost  effectiveness,  the  combination  of 
dexamethasone  and  metoclopramide  is  cost  effective  than  the  drug 
ondansetron  and  hence  can  be  used  as  good  anti-emetic  combination. 
Though there was mild sedation in certain patients where metoclopramide 
was administered, it did not create any problem but infact kept the patient 
calm and cool.
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PROFORMA
DEPARTMENT OF ANAESTHESIOLOGY 
MADURAI MEDICAL COLLEGE 
Dr.S.M.Senthilnathan, MDPG
PROPHYLACTIC ANTI-EMETICS IN PREVENTION OF PONV IN 
CAESAREAN SECTION UNDER SAB
Name of the patient : Date :    ASA Risk – I/II
Age : IP.NO :
Premedication : Inj Ranitidine 50 mg IV     Indication:
Group 
A – Inj glycopyrrolate 0.2mg IV
B – Inj ondansetron             IV
C – Inj Metaclopramide + Dexmethasone 8 mg IV  
D – Control 
Intra operative period
Time PR SBP SPO2
5 Min
10 
Min 
20 
Min 
30 
Min
45 
Min
1 Hr
Duration of Surgery 
Intra operative → Nausea / Vomiting / Retching 
Rescue anti-emetic → yes / No
APGAR OF BABY →
POST – OPERATIVE PERIOD FOR 4 HRS
Emesis score →
Sedation Score →
EMESIS SCORE 
0 – No Nausea 
1 - Mild nausea 
2 - Severe nausea 
3 – Retching 
4 - Vomiting once  
5 – Vomiting >1 time 
Ramsay Sedation Score 
1 – Anxious, agitated or restless 
2 – Co-operative but oriented
3 – Responds to commands
4 – Pt. asleep – responds to loud sound (Brisk response)
5 – Sluggish response
6 – No response 
